Skip to main content
Publications
Nance RM, Vannappagari V, Smith K, Johannes CB , Calingaert B , Saltus CW , Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC, Crane HM. Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings . J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):572-7. doi: 10.1097/QAI.0000000000002075
Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R , Zhou X , Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era . Br J Haematol. 2016 Mar;172(5):724-34. doi: 10.1111/bjh.13895
Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X , Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, Flowers CR. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States . Br J Haematol. 2015 Jul;170(1):85-95. doi: 10.1111/bjh.13399
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043
Harrison CN, Mesa RA, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X , Copley-Merriman C , Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy . Br J Haematol. 2013 Jul;162(2):229-39. doi: 10.1111/bjh.12375